Article | Published:

MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis

Nature Medicine volume 15, pages 5967 (2009) | Download Citation

Subjects

Abstract

We identified a previously undescribed gene associated with colon cancer by genome-wide expression analysis in primary and metastatic carcinomas: metastasis-associated in colon cancer-1, MACC1. MACC1 expression in tumor specimens is an independent prognostic indicator of metastasis formation and metastasis-free survival. We show that the gene encoding the hepatocyte growth factor (HGF) receptor, MET, is a transcriptional target of MACC1. MACC1 promotes proliferation, invasion and HGF-induced scattering of colon cancer cells in cell culture and tumor growth and metastasis in mouse models. These phenotypes are lost in cells expressing MACC1 mutants lacking the SH3 domain or the proline-rich motif. For clinical practice, MACC1 will be useful for the identification of poor prognosis subjects with colorectal cancer and is a promising new target for intervention in metastasis formation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

EMBL/GenBank/DDBJ

GenBank/EMBL/DDBJ

Protein Data Bank

References

  1. 1.

    New signals from the invasive front. Nature 441, 444–450 (2006).

  2. 2.

    & Clinical, biological and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 176, 61–80 (2007).

  3. 3.

    Staging of cancer of the colon and rectum. Cancer 70, 1393–1396 (1992).

  4. 4.

    et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 43, 1348–1360 (2007).

  5. 5.

    & A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).

  6. 6.

    & A progression puzzle. Nature 418, 823 (2002).

  7. 7.

    & Cancer genes and the pathways they control. Nat. Med. 10, 789–799 (2004).

  8. 8.

    , , , & Colorectal cancer: genetics of development and metastasis. J. Gastroenterol. 41, 185–192 (2006).

  9. 9.

    , , & Expression and genomic profiling of colorectal cancer. Biochim. Biophys. Acta 1775, 103–137 (2007).

  10. 10.

    , , & Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915–925 (2003).

  11. 11.

    & The Met pathway: master switch and drug target in cancer progression. FASEB J. 20, 1611–1621 (2006).

  12. 12.

    & c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep. 9, 102–108 (2007).

  13. 13.

    et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802–804 (1991).

  14. 14.

    et al. C-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151–162 (2007).

  15. 15.

    et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found. Symp. 212, 230–240 (1997).

  16. 16.

    & Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 6, 637–645 (2006).

  17. 17.

    et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147–154 (1995).

  18. 18.

    & Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn. J. Clin. Oncol. 27, 378–383 (1997).

  19. 19.

    , , , & Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin. Exp. Metastasis 18, 639–649 (2000).

  20. 20.

    et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9, 1480–1488 (2003).

  21. 21.

    et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219–228 (2007).

  22. 22.

    & Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967–971 (1992).

  23. 23.

    et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat. Genet. 36, 40–45 (2004).

  24. 24.

    , , , & Cloning, chromosomal localization, and characterization of cDNA from a novel gene, SH3BP4, expressed by human corneal fibroblasts. Genomics 62, 519–524 (1999).

  25. 25.

    Survival analysis. Ch.6 (Wiley-Interscience, New York, 1998).

  26. 26.

    et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36, 4562–4569 (1976).

  27. 27.

    , & The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol. 121, 145–154 (1993).

  28. 28.

    & An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 77, 209–223 (1985).

  29. 29.

    et al. Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br. J. Cancer 87, 1328–1335 (2002).

  30. 30.

    & Assembly of cell regulatory systems through protein interaction domains. Science 300, 445–452 (2003).

  31. 31.

    Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem. J. 390, 641–653 (2005).

  32. 32.

    , & Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307–320 (2006).

  33. 33.

    The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215, 159–169 (1998).

  34. 34.

    et al. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Int. J. Oncol. 24, 1057–1067 (2004).

  35. 35.

    , , , & Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62, 5126–5128 (2002).

  36. 36.

    et al. A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth. Oncogene 26, 1078–1087 (2007).

  37. 37.

    et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003).

  38. 38.

    et al. Interplay between VHL/HIF1α and Wnt/β-catenin pathways during colorectal tumorigenesis. Oncogene 25, 3065–3070 (2006).

  39. 39.

    , , & Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol. 25, 3982–3996 (2005).

  40. 40.

    & Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185–2200 (1998).

  41. 41.

    et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479–1488 (2005).

  42. 42.

    et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 4, 1577–1584 (2005).

  43. 43.

    et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9, 1091–1099 (1994).

  44. 44.

    , , , & Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA 91, 4731–4735 (1994).

  45. 45.

    , , , & Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023–1034 (2001).

  46. 46.

    et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21, 1791–1799 (2002).

  47. 47.

    et al. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia 8, 353–363 (2006).

  48. 48.

    & Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12, 3657–3660 (2006).

  49. 49.

    et al. The metastasis-associated gene S100A4 is a novel target of β-catenin/T cell factor signaling in colon cancer. Gastroenterology 131, 1486–1500 (2006).

  50. 50.

    et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Cancer Metastasis Rev. 8, 82–88 (1989).

Download references

Acknowledgements

We thank M. Niederstrasser, K.-D. Wernecke and D. Brett for support on bioinformatics and biostatistics. We thank W. Haensch and C. Röcken for pathohistological evaluation of the tumors and I. Wendler for management of the tumor bank. We thank S. Habedank for immunohistochemistry of the tumors. We are grateful to H. Kalthoff and S. Haye for performing the orthotopic transplantation experiments, to D. Kobelt and U. Sack for performing the in vivo imaging and to W. Haider for carrying out the animal histopathology. We thank I. Kelch for generating the SW620 clones expressing MACC1 shRNA. We also thank Y. Liu (University of Pittsburgh) for providing us with the MET promoter constructs and C. Daly (Dublin City University) for designing the MACC1 siRNAs. We are thankful to R.H. Shoemaker, U. Schaeper and M. Becker for scientific discussions. The excellent technical assistance of M. Lemm, C. Fleuter, P. Hermann, L. Malcherek, A. Kopacek, J. Aumann, L. Bauer and C. Röefzaad is gratefully acknowledged. We are grateful to R. Hodge for critically reading the manuscript. This work was supported by a grant from the Wilhelm-Sander-Foundation, Germany.

Author information

Affiliations

  1. Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany.

    • Ulrike Stein
    • , Wolfgang Walther
    • , Franziska Arlt
    • , Janice Smith
    • , Iduna Fichtner
    •  & Walter Birchmeier
  2. Department of Surgery and Surgical Oncology, Robert-Rössle Cancer Hospital, Charité University Medicine Berlin, Lindenberger Weg 80, 13125 Berlin, Germany.

    • Ulrike Stein
    • , Wolfgang Walther
    • , Franziska Arlt
    • , Holger Schwabe
    •  & Peter M Schlag

Authors

  1. Search for Ulrike Stein in:

  2. Search for Wolfgang Walther in:

  3. Search for Franziska Arlt in:

  4. Search for Holger Schwabe in:

  5. Search for Janice Smith in:

  6. Search for Iduna Fichtner in:

  7. Search for Walter Birchmeier in:

  8. Search for Peter M Schlag in:

Corresponding author

Correspondence to Ulrike Stein.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figs. 1–6, Supplementary Tables 1 and 2 and Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.1889

Further reading